BRIDGEBIO PHARMA INC (BBIO) Stock Income Statement
NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 221.90M | 9.30M | 77.65M | 69.72M | 8.25M | |||
| Minority Interest Expense | 7.58M | 10.05M | 3.47M | 23.92M | 56.76M | |||
| Cost Of Goods | 3.88M | 2.45M | 3.43M | 3.11M | 0.00 | |||
| Gross Profit | 218.02M | 6.86M | 74.21M | 66.60M | 8.25M | |||
| Operating Expenses | 795.39M | 606.30M | 542.65M | 643.24M | 482.73M | |||
| Research and Development | 506.46M | 455.71M | 399.46M | 451.02M | 337.05M | |||
| Selling, General, and Administrative Expenses | 288.93M | 150.59M | 143.19M | 192.21M | 145.68M | |||
| Operating Income | -577.37M | -599.44M | -468.43M | -576.63M | -474.48M | |||
| Interest Income/Expense | -105.09M | -44.94M | 35.05M | -45.65M | -32.64M | |||
| Other Income/Expense | 4.14M | -944.00K | -7.50M | 35.82M | 1.63M | |||
| Non Recurring Items | 136.13M | -7.93M | -43.77M | N/A | N/A | |||
| Income Before Taxes | -542.19M | -653.25M | -484.65M | -586.45M | -505.49M | |||
| Income Tax | 1.15M | N/A | N/A | N/A | N/A | |||
| Net Income | -535.76M | -643.20M | -481.18M | -562.54M | -448.72M | |||
| EBITDA | -571.29M | -592.95M | -461.66M | -570.79M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.88 | -3.95 | -3.26 | -3.90 | -3.80 | |||
| Non GAAP EPS | -3.09 | -3.94 | -3.11 | -3.91 | -3.80 | |||
| Statistics | ||||||||
| Gross Profit Margin | 98.25% | 73.71% | 95.57% | 95.52% | 100.00% | |||
| Profit Margin | -241.44% | -6913.92% | -619.68% | -806.86% | -5439.03% | |||
| Operating Profit Margin | -260.19% | -6443.56% | -603.26% | -827.07% | -5751.27% | |||
All data in USD